{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T18:35:54Z","timestamp":1771007754799,"version":"3.50.1"},"reference-count":108,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Diagnostic Pathology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1053\/j.semdp.2023.04.007","type":"journal-article","created":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T17:36:45Z","timestamp":1681407405000},"page":"187-194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Advances in molecular evaluation of myeloproliferative neoplasms"],"prefix":"10.1053","volume":"40","author":[{"given":"Nianyi","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6630-4128","authenticated-orcid":false,"given":"C. Cameron","family":"Yin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1053\/j.semdp.2023.04.007_bib0001","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms","volume":"36","author":"Khoury","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.semdp.2023.04.007_bib0002","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1038\/s41467-021-23097-w","article-title":"Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia","volume":"12","author":"Ochi","year":"2021","journal-title":"Nat Commun"},{"issue":"11","key":"10.1053\/j.semdp.2023.04.007_bib0003","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1053\/j.semdp.2023.04.007_bib0004","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"issue":"25","key":"10.1053\/j.semdp.2023.04.007_bib0005","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1182\/blood-2008-07-166694","article-title":"Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy","volume":"113","author":"Quint\u00e1s-Cardama","year":"2009","journal-title":"Blood"},{"issue":"22","key":"10.1053\/j.semdp.2023.04.007_bib0006","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1182\/blood-2016-01-690230","article-title":"Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy","volume":"127","author":"Wang","year":"2016","journal-title":"Blood"},{"issue":"26","key":"10.1053\/j.semdp.2023.04.007_bib0007","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1182\/bloodadvances.2017011858","article-title":"Cytogenetics\u2013based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy","volume":"1","author":"Gong","year":"2017","journal-title":"Blood Adv"},{"issue":"1","key":"10.1053\/j.semdp.2023.04.007_bib0008","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ajh.24943","article-title":"Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors","volume":"93","author":"Alhuraiji","year":"2018","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1053\/j.semdp.2023.04.007_bib0009","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1182\/bloodadvances.2020003570","article-title":"Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression","volume":"5","author":"Clark","year":"2021","journal-title":"Blood Adv"},{"key":"10.1053\/j.semdp.2023.04.007_bib0010","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1309\/H8JH6L094B9U3HGT","article-title":"t(8;21)(q22;q22) in blast phase of chronic myelogenous leukemia","volume":"121","author":"Yin","year":"2004","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"10.1053\/j.semdp.2023.04.007_bib0011","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1309\/3HFE16DKMB1DBFMN","article-title":"inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: a clinicopathologic, cytogenetic, and molecular study of five cases","volume":"124","author":"Merzianu","year":"2005","journal-title":"Am J Clin Pathol"},{"key":"10.1053\/j.semdp.2023.04.007_bib0012","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1002\/cncr.21797","article-title":"t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy","volume":"106","author":"Yin","year":"2006","journal-title":"Cancer"},{"issue":"4","key":"10.1053\/j.semdp.2023.04.007_bib0013","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s12308-012-0172-6","article-title":"t(15;17)(q24.1;q21.2)\/PML-RARA in blast phase of chronic myelogenous leukemia: a unique clonal evolution","volume":"6","author":"Hoehn","year":"2013","journal-title":"J Hematopathol"},{"issue":"19","key":"10.1053\/j.semdp.2023.04.007_bib0014","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1182\/blood-2017-07-792143","article-title":"Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment","volume":"130","author":"Issa","year":"2017","journal-title":"Blood"},{"issue":"6","key":"10.1053\/j.semdp.2023.04.007_bib0015","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.3324\/haematol.2018.208801","article-title":"Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia","volume":"104","author":"Bidet","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"10.1053\/j.semdp.2023.04.007_bib0016","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1038\/leu.2014.272","article-title":"Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status","volume":"28","author":"Schmidt","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.semdp.2023.04.007_bib0017","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood-2016-04-708560","article-title":"Spectrum of somatic mutation dynamics in chronic myeloid leukemia following tyrosine kinase inhibitor therapy","volume":"129","author":"Kim","year":"2017","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.semdp.2023.04.007_bib0018","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1182\/blood-2018-02-832253","article-title":"Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk disease","volume":"132","author":"Branford","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.semdp.2023.04.007_bib0019","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1038\/s41375-019-0512-y","article-title":"Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia","volume":"33","author":"Branford","year":"2019","journal-title":"Leukemia"},{"key":"10.1053\/j.semdp.2023.04.007_bib0020","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1038\/s41375-018-0157-2","article-title":"Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia","volume":"32","author":"Ernst","year":"2018","journal-title":"Leukemia"},{"issue":"12","key":"10.1053\/j.semdp.2023.04.007_bib0021","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.3324\/haematol.2018.200220","article-title":"Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors","volume":"104","author":"Nteliopoulos","year":"2019","journal-title":"Haematologica"},{"issue":"10","key":"10.1053\/j.semdp.2023.04.007_bib0022","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41408-022-00742-1","article-title":"Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia","volume":"12","author":"Bidikian","year":"2022","journal-title":"Blood Cancer J"},{"issue":"9","key":"10.1053\/j.semdp.2023.04.007_bib0023","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1038\/s41375-022-01648-4","article-title":"ASXL1 mutations predict inferior molecular response to nilotinib treatment in chronic myeloid leukemia","volume":"36","author":"Schonfeld","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"10.1053\/j.semdp.2023.04.007_bib0024","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1038\/bcj.2013.54","article-title":"ASXL1, TP53 and IKZF3 mutations are present in the chronic phase and blast phase of chronic myeloid leukemia","volume":"8","author":"Menezes","year":"2013","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1053\/j.semdp.2023.04.007_bib0025","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/leu.2011.139","article-title":"Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia","volume":"25","author":"Roche-Lestienne","year":"2011","journal-title":"Leukemia"},{"issue":"10","key":"10.1053\/j.semdp.2023.04.007_bib0026","doi-asserted-by":"crossref","first-page":"E623","DOI":"10.1002\/ajh.24865","article-title":"Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients","volume":"92","author":"Mologni","year":"2017","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1053\/j.semdp.2023.04.007_bib0027","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1182\/bloodadvances.2019000943","article-title":"Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia","volume":"4","author":"Adnan Awad","year":"2020","journal-title":"Blood Adv"},{"issue":"4","key":"10.1053\/j.semdp.2023.04.007_bib0028","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-022-00667-9","article-title":"Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation","volume":"12","author":"Adnan Awad","year":"2022","journal-title":"Blood Cancer J"},{"issue":"3","key":"10.1053\/j.semdp.2023.04.007_bib0029","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/leu.2010.298","article-title":"A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"issue":"4","key":"10.1053\/j.semdp.2023.04.007_bib0030","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1038\/s41375-020-01011-5","article-title":"RUNX1 mutations in blast-phase chronic myeloid leukemia associated with distinct phenotypes, transcriptional profiles, and drug responses","volume":"35","author":"Adnan Awad","year":"2021","journal-title":"Leukemia"},{"issue":"7191","key":"10.1053\/j.semdp.2023.04.007_bib0031","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature06866","article-title":"BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros","volume":"453","author":"Mullighan","year":"2008","journal-title":"Nature"},{"issue":"1","key":"10.1053\/j.semdp.2023.04.007_bib0032","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.semdp.2023.04.007_bib0033","unstructured":"Network N.C.C. Chronic myeloid leukemia. Version 3.2022. NCCN clinical practice guidelines in oncology: chronic myeloid leukemia. Online; 2022."},{"issue":"9464","key":"10.1053\/j.semdp.2023.04.007_bib0034","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"issue":"7037","key":"10.1053\/j.semdp.2023.04.007_bib0035","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"issue":"17","key":"10.1053\/j.semdp.2023.04.007_bib0036","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1053\/j.semdp.2023.04.007_bib0037","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1053\/j.semdp.2023.04.007_bib0038","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLos Med"},{"issue":"25","key":"10.1053\/j.semdp.2023.04.007_bib0039","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"10.1053\/j.semdp.2023.04.007_bib0040","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1053\/j.semdp.2023.04.007_bib0041","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s11899-022-00685-1","article-title":"Mullally. Molecular pathogenesis of myeloproliferative neoplasms","volume":"17","author":"Rolles","year":"2022","journal-title":"Curr Hematol Malig Rep"},{"issue":"7","key":"10.1053\/j.semdp.2023.04.007_bib0042","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa1412098","article-title":"Effect of mutation order on myeloproliferative neoplasms","volume":"372","author":"Ortmann","year":"2015","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.semdp.2023.04.007_bib0043","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s002770050595","article-title":"Dual implication of fibrogenic cytokines in the pathogenesis of fibrosis and myeloproliferation in myeloid metaplasia with myelofibrosis","volume":"78","author":"Le Bousse-Kerdil\u00e8s","year":"1999","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1053\/j.semdp.2023.04.007_bib0044","doi-asserted-by":"crossref","first-page":"101378","DOI":"10.1016\/j.beha.2022.101378","article-title":"Challenges of diagnosing and managing pre-fibrotic myelofibrosis: a case-based and practical approach","volume":"35","author":"Rampotas","year":"2022","journal-title":"Best Pract Res Clin Haematol"},{"issue":"19","key":"10.1053\/j.semdp.2023.04.007_bib0045","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1002\/cncr.31663","article-title":"Bone marrow core biopsy in 508 consecutive patients with chronic myeloid leukemia: assessment of potential value","volume":"124","author":"Hidalgo-L\u03ccpez","year":"2018","journal-title":"Cancer"},{"issue":"8","key":"10.1053\/j.semdp.2023.04.007_bib0046","first-page":"1128","article-title":"European consensus on grading bone marrow fibrosis and assessment of cellularity","volume":"90","author":"Thiele","year":"2005","journal-title":"Haematologica"},{"issue":"4","key":"10.1053\/j.semdp.2023.04.007_bib0047","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1177\/00037028211063513","article-title":"Polarization sensitive photothermal mid-infrared spectroscopic imaging of human bone marrow tissue","volume":"76","author":"Mankar","year":"2022","journal-title":"Appl Spectrosc"},{"key":"10.1053\/j.semdp.2023.04.007_bib0048","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1038\/leu.2013.119","article-title":"Mutations and prognosis in primary myelofibrosis","volume":"27","author":"Vannucchi","year":"2013","journal-title":"Leukemia"},{"issue":"9","key":"10.1053\/j.semdp.2023.04.007_bib0049","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients","volume":"28","author":"Guglielmelli","year":"2014","journal-title":"Leukemia"},{"issue":"15","key":"10.1053\/j.semdp.2023.04.007_bib0050","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1182\/blood-2014-07-588426","article-title":"The prognostic advantage of calreticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants","volume":"124","author":"Tefferi","year":"2014","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.semdp.2023.04.007_bib0051","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1038\/bcj.2015.90","article-title":"Validation of the differential prognostic impact of type1\/type 1-like versus type 2\/type 2-like CALR mutations in myelofibrosis","volume":"5","author":"Guglielmelli","year":"2015","journal-title":"Blood Cancer J"},{"issue":"12","key":"10.1053\/j.semdp.2023.04.007_bib0052","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/ajh.25230","article-title":"Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management","volume":"93","author":"Tefferi","year":"2018","journal-title":"Am J Hematol"},{"issue":"7","key":"10.1053\/j.semdp.2023.04.007_bib0053","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/ajh.24377","article-title":"Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: a study on 359 patients of the AGIMM group","volume":"91","author":"Rotunno","year":"2016","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1053\/j.semdp.2023.04.007_bib0054","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/bjh.16380","article-title":"Mutation-enhanced internal prognostic systems for essential thrombocythaemia and polycythaemia vera","volume":"189","author":"Tefferi","year":"2020","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1053\/j.semdp.2023.04.007_bib0055","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1046\/j.1365-2141.2000.02242.x","article-title":"The incidences of trisomy 8, trisomy 9 and D20S108 deletion in polycythaemia vera: an analysis of blood granulocytes using interphase fluorescence in situ hybridization","volume":"110","author":"Westwood","year":"2000","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1053\/j.semdp.2023.04.007_bib0056","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41408-022-00639-z","article-title":"Cytogenetic abnormalities in essential thrombocythemia: clinical and molecular correlates and prognostic relevance in 809 informative cases","volume":"23","author":"Gangat","year":"2022","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1053\/j.semdp.2023.04.007_bib0057","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/j.1365-2141.2005.05593.x","article-title":"Der(6)t(1;6)(q21-23;p21.3): a specific cytogenetic abnormality in myelofibrosis with myeloid metaplasia","volume":"130","author":"Dingli","year":"2005","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1053\/j.semdp.2023.04.007_bib0058","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1600-0609.2009.01224.x","article-title":"Conventional cytogenetics in myelofibrosis: literature review and discussion","volume":"82","author":"Hussein","year":"2009","journal-title":"Eur J Haematol"},{"issue":"4","key":"10.1053\/j.semdp.2023.04.007_bib0059","first-page":"392","article-title":"DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"Clin Oncol"},{"issue":"11","key":"10.1053\/j.semdp.2023.04.007_bib0060","doi-asserted-by":"crossref","first-page":"e366","DOI":"10.1038\/bcj.2015.95","article-title":"Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors","volume":"5","author":"Cerqipzzi","year":"2015","journal-title":"Blood Cancer J"},{"issue":"2","key":"10.1053\/j.semdp.2023.04.007_bib0061","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41408-019-0175-y","article-title":"Leukemic transformation among 1306 patients with primary myelofibrosis: risk factors and development of a predictive model","volume":"9","author":"Vallapureddy","year":"2019","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1053\/j.semdp.2023.04.007_bib0062","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1159\/000512929","article-title":"Accelerated phase of myeloproliferative neoplasms","volume":"144","author":"Shahin","year":"2021","journal-title":"Acta Haematol"},{"issue":"9","key":"10.1053\/j.semdp.2023.04.007_bib0063","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1158\/2159-8290.CD-19-0152","article-title":"Loss of EZH2 reporgrams BCAA metabolism to drive leukemic transformation","volume":"9","author":"Gu","year":"2019","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1053\/j.semdp.2023.04.007_bib0064","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1158\/0008-5472.CAN-09-3783","article-title":"Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias","volume":"70","author":"Abdel-Wahab","year":"2010","journal-title":"Cancer Res"},{"issue":"11","key":"10.1053\/j.semdp.2023.04.007_bib0065","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1002\/ajh.23309","article-title":"Clinical significance of genetic aberrations in secondary acute myeloid leukemia","volume":"87","author":"Milosevic","year":"2012","journal-title":"Am J Hematol"},{"issue":"50","key":"10.1053\/j.semdp.2023.04.007_bib0066","doi-asserted-by":"crossref","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","article-title":"Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms","volume":"111","author":"Rampal","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"10.1053\/j.semdp.2023.04.007_bib0067","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1038\/s41375-020-0778-0","article-title":"A phase 1\/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia","volume":"34","author":"Bose","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1053\/j.semdp.2023.04.007_bib0068","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/blood-2006-12-062125","article-title":"Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for JAK2-V617F mutation","volume":"110","author":"Theocharides","year":"2007","journal-title":"Blood"},{"issue":"14","key":"10.1053\/j.semdp.2023.04.007_bib0069","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","article-title":"Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm","volume":"115","author":"Beer","year":"2010","journal-title":"Blood"},{"issue":"19","key":"10.1053\/j.semdp.2023.04.007_bib0070","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1053\/j.semdp.2023.04.007_bib0071","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood-2013-05-500959","article-title":"The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment","volume":"122","author":"Gotlib","year":"2013","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.semdp.2023.04.007_bib0072","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/leu.2013.122","article-title":"CSF3R is a highly prevalent and specific mutation in chronic neutrophilic leukemia","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"issue":"10","key":"10.1053\/j.semdp.2023.04.007_bib0073","first-page":"1006","article-title":"Efficacy of Ruxolitinib in patients with chronic neutrophilic leukemia and atypical chronic myeloid leukemia","volume":"138","author":"Dao","year":"2020","journal-title":"Clin Oncol"},{"key":"10.1053\/j.semdp.2023.04.007_bib0074","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.exphem.2016.10.008","article-title":"Granulocyte colony-stimulating factor receptor signaling in severe congenital neutropenia, chronic neutrophilic leukemia, and related malignancies","volume":"46","author":"Dwivedi","year":"2017","journal-title":"Exp Hematol"},{"issue":"4","key":"10.1053\/j.semdp.2023.04.007_bib0075","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1002\/ajh.24983","article-title":"Chronic neutrophilic leukemia: 2018 update on diagnosis, molecular genetics and management","volume":"93","author":"Elliott","year":"2018","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1053\/j.semdp.2023.04.007_bib0076","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1038\/leu.2014.39","article-title":"Chronic neutrophilic leukemia with concurrent CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibitors and lack of treatment response to ruxolitinib","volume":"28","author":"Lasho","year":"2014","journal-title":"Leukemia"},{"issue":"7","key":"10.1053\/j.semdp.2023.04.007_bib0077","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ajh.24031","article-title":"ASXL1 mutations are frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia","volume":"90","author":"Elliott","year":"2015","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1053\/j.semdp.2023.04.007_bib0078","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/MOH.0000000000000114","article-title":"Chronic neutrophilic leukemia: novel mutations and their impact on clinical practice","volume":"22","author":"Tefferi","year":"2015","journal-title":"Curr Opin Hematol"},{"issue":"2","key":"10.1053\/j.semdp.2023.04.007_bib0079","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ajh.25688","article-title":"Chronic neutrophilic leukemia: 2020 update on diagnosis, molecular genetics, prognosis and management","volume":"95","author":"Szuber","year":"2020","journal-title":"Am J Hematol"},{"key":"10.1053\/j.semdp.2023.04.007_bib0080","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"p54","author":"Bain","year":"2017"},{"key":"10.1053\/j.semdp.2023.04.007_bib0081","doi-asserted-by":"crossref","unstructured":"Tzankov A., Reichard K.K., Hasserjian R.P., Arber D.A., Orazi A., Wang S.A. Updates on eosinophilic disorders. Virchows Arch 2022 Sep 7. Online ahead of print.","DOI":"10.1007\/s00428-022-03402-8"},{"issue":"9","key":"10.1053\/j.semdp.2023.04.007_bib0082","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1038\/leu.2016.73","article-title":"Predictors of survival in WHO-defined hypereosinophilic syndrome and idiopathic hypereosinophilia and the role of next-generation sequencing","volume":"30","author":"Pardanani","year":"2016","journal-title":"Leukemia"},{"issue":"8","key":"10.1053\/j.semdp.2023.04.007_bib0083","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1038\/modpathol.2016.75","article-title":"Targeted next-generation sequencing identifies a subset of idiopathic hypereosinophilic syndrome with features similar to chronic eosinophilic leukemia, not otherwise specified","volume":"29","author":"Wang","year":"2016","journal-title":"Mod Pathol"},{"issue":"10","key":"10.1053\/j.semdp.2023.04.007_bib0084","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0185602","article-title":"Idiopathic hypereosinophilia is clonal disorder? Clonality identified by targeted sequencing","volume":"12","author":"Lee","year":"2017","journal-title":"PLoS ONE"},{"issue":"2","key":"10.1053\/j.semdp.2023.04.007_bib0085","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/s41375-018-0342-3","article-title":"Recurrent activating STAT5B N642H mutation in myeloid neoplasms with eosinophilia","volume":"33","author":"Cross","year":"2019","journal-title":"Leukemia"},{"issue":"18","key":"10.1053\/j.semdp.2023.04.007_bib0086","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1182\/bloodadvances.2021004237","article-title":"A novel activating JAK1 mutation in chronic eosinophilic leukemia","volume":"5","author":"Shomali","year":"2021","journal-title":"Blood Adv"},{"key":"10.1053\/j.semdp.2023.04.007_bib0087","first-page":"6","article-title":"Chronic eosinophilic leukemia, NOS with t(5;12)(q31;p13)\/ETV6-ACSL6 gene fusion: a novel variant of myeloid proliferative neoplasm with eosinophilia","volume":"5","author":"Su","year":"2016","journal-title":"Human Pathol"},{"issue":"8","key":"10.1053\/j.semdp.2023.04.007_bib0088","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.3324\/haematol.2017.165340","article-title":"Bone marrow morphology is a strong discriminator between chronic eosinophilic leukemia, not otherwise specified and reactive idiopathic hypereosinophilic syndrome","volume":"102","author":"Wang","year":"2017","journal-title":"Haematologica"},{"issue":"2","key":"10.1053\/j.semdp.2023.04.007_bib0089","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/ajcp\/aqaa244","article-title":"Eosinophilia\/hypereosinophilia in the setting of reactive and idiopathic causes, well-defied myeloid or lymphoid leukemias, or germline disodres","volume":"155","author":"Kelemen","year":"2021","journal-title":"Am J Clin Pathol"},{"issue":"24","key":"10.1053\/j.semdp.2023.04.007_bib0090","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJM199706123362404","article-title":"Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders","volume":"336","author":"Side","year":"1997","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1053\/j.semdp.2023.04.007_bib0091","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/sj.leu.2401240","article-title":"RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML)","volume":"12","author":"Flotho","year":"1999","journal-title":"Leukemia"},{"issue":"2","key":"10.1053\/j.semdp.2023.04.007_bib0092","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ng1156","article-title":"Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia","volume":"34","author":"Tartaglia","year":"2003","journal-title":"Nat Genet"},{"issue":"9","key":"10.1053\/j.semdp.2023.04.007_bib0093","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood-2009-01-198416","article-title":"Mutations in CBL occur frequently in juvenile myelomonocytic leukemia","volume":"114","author":"Loh","year":"2009","journal-title":"Blood"},{"issue":"10","key":"10.1053\/j.semdp.2023.04.007_bib0094","first-page":"3534","article-title":"Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European working group on myelodysplastic syndromes in childhood (EWOG-MDS)","volume":"89","author":"Niemeyer","year":"1997","journal-title":"Blood"},{"issue":"26","key":"10.1053\/j.semdp.2023.04.007_bib0095","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.1182\/blood-2009-12-260729","article-title":"Long-term survival after nonintensive chemotherapy in some juvenile myelomonocytic leukemia patients with CBL mutations, and the possible presence of healthy persons with the mutations","volume":"115","author":"Matsuda","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1053\/j.semdp.2023.04.007_bib0096","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1038\/ng.641","article-title":"Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia","volume":"42","author":"Niemeyer","year":"2010","journal-title":"Nat Genet"},{"issue":"11","key":"10.1053\/j.semdp.2023.04.007_bib0097","doi-asserted-by":"crossref","first-page":"4243","DOI":"10.1182\/blood-2003-08-2650","article-title":"Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder","volume":"103","author":"Le","year":"2004","journal-title":"Blood"},{"issue":"5","key":"10.1053\/j.semdp.2023.04.007_bib0098","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1182\/blood-2005-11-011486","article-title":"Interstitial uniparental isodisomy at clustered breakpoint intervals is a frequent mechanism of NF1 inactivation in myeloid malignancies","volume":"108","author":"Stephens","year":"2006","journal-title":"Blood"},{"issue":"2","key":"10.1053\/j.semdp.2023.04.007_bib0099","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3324\/haematol.2009.010355","article-title":"Mitotic recombination and compound-heterozygous mutations are predominant NF1-inactivating mechanisms in children with juvenile myelomonocytic leukemia and neurofibromatosis type 1","volume":"95","author":"Steinemann","year":"2010","journal-title":"Haematologica"},{"issue":"11","key":"10.1053\/j.semdp.2023.04.007_bib0100","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1038\/ng.3400","article-title":"The genomic landscape of juvenile myelomonocytic leukemia","volume":"47","author":"Stieglitz","year":"2015","journal-title":"Nat Genet"},{"issue":"14","key":"10.1053\/j.semdp.2023.04.007_bib0101","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1182\/blood-2017-07-798157","article-title":"Integrated molecular profiling of juvenile myelomonocytic leukemia","volume":"131","author":"Murakami","year":"2018","journal-title":"Blood"},{"issue":"8","key":"10.1053\/j.semdp.2023.04.007_bib0102","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/ng.2698","article-title":"Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia","volume":"45","author":"Sakaguchi","year":"2013","journal-title":"Nat Genet"},{"issue":"1","key":"10.1053\/j.semdp.2023.04.007_bib0103","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2141.2010.08196.x","article-title":"Spectrum of molecular defects in juvenile myelomonocytic leukaemia","volume":"150","author":"Sugimoto","year":"2010","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1053\/j.semdp.2023.04.007_bib0104","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/ng.3420","article-title":"Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network","volume":"47","author":"Caye","year":"2015","journal-title":"Nat Genet"},{"issue":"18","key":"10.1053\/j.semdp.2023.04.007_bib0105","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1182\/blood-2010-08-298968","article-title":"Aberrant DNA methylation characterizes juvenile myelomonocytic leukemia with poor outcome","volume":"117","author":"Olk-Batz","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1053\/j.semdp.2023.04.007_bib0106","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1038\/s41467-017-02177-w","article-title":"RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia","volume":"8","author":"Lipka","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"10.1053\/j.semdp.2023.04.007_bib0107","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-017-02178-9","article-title":"Genome-wide DNA methylation is predictive of outcome in juvenile myelomonocytic leukemia","volume":"8","author":"Stieglitz","year":"2017","journal-title":"Nat Commun"},{"key":"10.1053\/j.semdp.2023.04.007_bib0108","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"p57","author":"Kvasnicka","year":"2017"}],"container-title":["Seminars in Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740257023000369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0740257023000369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T19:23:25Z","timestamp":1760037805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0740257023000369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":108,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S0740257023000369"],"URL":"https:\/\/doi.org\/10.1053\/j.semdp.2023.04.007","relation":{},"ISSN":["0740-2570"],"issn-type":[{"value":"0740-2570","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in molecular evaluation of myeloproliferative neoplasms","name":"articletitle","label":"Article Title"},{"value":"Seminars in Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.semdp.2023.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}